Employers to Cut GLP-1 Obesity Drug Coverage in 2027, Impacting Eli Lilly
LLY sits 82% above its 52-week low of $623.78.
Summary
Some US employers are planning to drop coverage of GLP-1 obesity drugs in 2027, with surveys indicating 5-10% of employers intend to cease coverage. This follows Cigna's decision to stop covering these treatments for its own employees. This development introduces a significant headwind for Eli Lilly, which has recently secured FDA approval for its new oral weight-loss pill Foundayo and reported strong growth driven by GLP-1s like Mounjaro and Zepbound. Reduced employer coverage directly impacts patient access and sales volume for Eli Lilly's key growth drivers, potentially offsetting the benefits of lower drug prices and increased demand for oral options.
At the time of this announcement, LLY was trading at $1,137.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,182.73. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.